Nuvalent
preclinical characterization demonstrates desired target product profile inhibited diverse alk fusions and resistance mutations in activity in activity potent activity against alk driven cell lines including alk single and compound mutants tumor regression at well tolerated doses in alk models including alk single and compound mutants i is a eye of a a a a i i a a a a vehicle call lines alk fusion day cell viability assay no resistance mutations a a a a a a a a a i models harboring alk fusion no resistance mutations hip alk alk alk alk me alk a alk bid bid or in some cases dosing was not performed on weekends bid twice daily half maximal inhibitory concentration orally once daily variant sources lin lee a a data also reflect additional repeat testing and models | Nuvalent
Company
Deck Type
Sector
Industry
Deck date
January 2024
Slide
15 of 42
Similar slides by Nuvalent
See diffirences between slides (animation)
Investor Presentation
April 2024
preclinical characterization demonstrates desired target product profile inhibited diverse alk fusions and resistance mutations in activity in activity potent activity against alk driven cell lines including alk single and compound mutants tumor regression at well tolerated doses in alk models including alk single and compound mutants a a a a a a poe arn i i a vehicle cell lines harboring alk fusion day cell viability assay no resistance mutations a a a a a a a a a models harboring alk fusion no resistance mutations hip alk a i alk mem alk alk alk a alk bid bid or in some cases dosing was not performed on weekends bid twice daily half maximal inhibitory concentration orally once daily variant sources lin lee data also reflect additional repeat testing models a a | Nuvalent
Investor Presentation
February 2024
preclinical characterization demonstrates desired target product profile inhibited diverse alk fusions and resistance mutations in activity in activity potent activity against alk driven cell lines including alk single and compound mutants tumor regression at well tolerated doses in alk models including alk single and compound mutants a so apt of me gee a a a eer ere a a a a vehicle cell lines harboring alk fusion a no resistance mutations a day cell viability assay a a a a a bid twice daily half maximal inhibitory concentration orally once daily variant models harboring alk fusion no resistance mutations hip alk alk alk alk alk a alk bid bid or in some cases dosing was not performed on weekends sources lin data also reflect additional repeat testing and models lee a a a | Nuvalent
Investor Presentation
January 2024
preclinical characterization demonstrates desired target product profile inhibited diverse alk fusions and resistance mutations in activity in activity potent activity against alk driven cell lines including alk single and compound mutants tumor regression at well tolerated doses in alk models including alk single and compound mutants i is a eye of a a a a i i a a a a vehicle call lines alk fusion day cell viability assay no resistance mutations a a a a a a a a a i models harboring alk fusion no resistance mutations hip alk alk alk alk me alk a alk bid bid or in some cases dosing was not performed on weekends bid twice daily half maximal inhibitory concentration orally once daily variant sources lin lee a a data also reflect additional repeat testing and models | Nuvalent
Investor Presentation
November 2023
preclinical inhibited diverse alk fusions and resistance mutations | Nuvalent
Related slides by other companies
Immix Biopharma
Investor Presentation
October 2023
pancreatic preclinical mouse model outperforms gem pac | Immix Biopharma
Immix Biopharma
Investor Presentation
November 2023
pancreatic preclinical mouse model outperforms gem pac | Immix Biopharma
Exscientia
Results
May 2022
identifying novel pathways | Exscientia
Immix Biopharma
Investor Presentation
November 2023
pancreatic preclinical mouse model outperforms gem pac | Immix Biopharma
Other recent decks by Nuvalent
See all presentations (10 decks)
Investor Presentation
April 2024
Investor Presentation
February 2024
Investor Presentation
January 2024
Investor Presentation
November 2023
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights